The emerging therapy of the medication represents a exciting development in the handling of type 2 diabetes. Unlike existing medications, tirzepatide impacts two pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – providing enhanced sugar control an